- 作者: Li-Kai Huang, Yi-Chun Kuan, Ho-Wei Lin & Chaur-Jong Hu
- 作者服務機構: 1.Dementia Center and Department of Neurology, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 2.Department of Biomedical Engineering, National Taiwan University, Taipei, Taiwan 3.Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 4.PhD Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, No. 291, Zhong Zheng Road, Zhonghe District, New Taipei City, Taiwan 5.School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 6.Taipei Neuroscience Institute, Taipei Medical University, New Taipei City, Taiwan
- 中文摘要:
- 英文摘要:
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury. Clinical trials focusing on new drugs for AD were documented in 2020, but subsequent developments have emerged since then. Notably, the US-FDA has approved Aducanumab and Lecanemab, both antibodies targeting amyloid, marking the end of a nearly two-decade period without new AD drugs. In this comprehensive report, we review all trials listed in clinicaltrials.gov, elucidating their underlying mechanisms and study designs. Ongoing clinical trials are investigating numerous promising new drugs for AD. The main trends in these trials involve pathophysiology-based, disease-modifying therapies and the recruitment of participants in earlier stages of the disease. These trends underscore the significance of conducting fundamental research on pathophysiology, prevention, and intervention prior to the occurrence of brain damage caused by AD. - 中文關鍵字:
- 英文關鍵字: Alzheimer disease, Clinical trials, Anti-amyloid, Anti-tau, Neuroprotection, Cognitive enhancement, Neuroinfammation